Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen.
Identifieur interne : 000631 ( PubMed/Corpus ); précédent : 000630; suivant : 000632Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen.
Auteurs : A M Bal ; M Z David ; J. Garau ; T. Gottlieb ; T. Mazzei ; F. Scaglione ; P. Tattevin ; I M GouldSource :
- Journal of global antimicrobial resistance [ 2213-7173 ] ; 2017.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major public health problem. Vancomycin and teicoplanin have been in clinical use for several decades but their drawbacks are well described. In the last 10 years, several antibiotics have been made available for clinical use. Daptomycin and linezolid have been extensively used during this period. Other agents such as ceftaroline, ceftobiprole, dalbavancin, oritavancin, tedizolid and telavancin have been approved by regulatory agencies since 2009. Many others, such as the newer tetracyclines, fluoroquinolones, oxazolidinones and pleuromutilins, are in various stages of development. In addition, an ongoing multicentre trial is investigating the role of combination of vancomycin or daptomycin with β-lactam antibiotics. This review discusses the role of the newer antibiotics, reflecting the views of the 6th MRSA Consensus Conference meeting of the International Society of Chemotherapy MRSA Working Group that took place in 2016.
DOI: 10.1016/j.jgar.2017.05.019
PubMed: 28732783
Links to Exploration step
pubmed:28732783Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen.</title><author><name sortKey="Bal, A M" sort="Bal, A M" uniqKey="Bal A" first="A M" last="Bal">A M Bal</name><affiliation><nlm:affiliation>Department of Microbiology, University Hospital Crosshouse, Kilmarnock KA2 0BE, UK. Electronic address: abhijit.bal@nhs.net.</nlm:affiliation></affiliation></author><author><name sortKey="David, M Z" sort="David, M Z" uniqKey="David M" first="M Z" last="David">M Z David</name><affiliation><nlm:affiliation>Departments of Medicine, Paediatrics, and Public Health Sciences, University of Chicago, Chicago, IL 60637, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Garau, J" sort="Garau, J" uniqKey="Garau J" first="J" last="Garau">J. Garau</name><affiliation><nlm:affiliation>Department of Medicine, Hospital Universitari Mútua de Terrassa, Plaza Dr Robert 5, Barcelona 08221, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Gottlieb, T" sort="Gottlieb, T" uniqKey="Gottlieb T" first="T" last="Gottlieb">T. Gottlieb</name><affiliation><nlm:affiliation>Department of Microbiology and Infectious Diseases, Concord Hospital, Sydney, NSW 2139, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Mazzei, T" sort="Mazzei, T" uniqKey="Mazzei T" first="T" last="Mazzei">T. Mazzei</name><affiliation><nlm:affiliation>Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Firenze, Firenze, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Scaglione, F" sort="Scaglione, F" uniqKey="Scaglione F" first="F" last="Scaglione">F. Scaglione</name><affiliation><nlm:affiliation>Department of Oncology and Onco-Haematology, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Tattevin, P" sort="Tattevin, P" uniqKey="Tattevin P" first="P" last="Tattevin">P. Tattevin</name><affiliation><nlm:affiliation>Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, 35033 Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gould, I M" sort="Gould, I M" uniqKey="Gould I" first="I M" last="Gould">I M Gould</name><affiliation><nlm:affiliation>Department of Microbiology, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28732783</idno><idno type="pmid">28732783</idno><idno type="doi">10.1016/j.jgar.2017.05.019</idno><idno type="wicri:Area/PubMed/Corpus">000631</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000631</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen.</title><author><name sortKey="Bal, A M" sort="Bal, A M" uniqKey="Bal A" first="A M" last="Bal">A M Bal</name><affiliation><nlm:affiliation>Department of Microbiology, University Hospital Crosshouse, Kilmarnock KA2 0BE, UK. Electronic address: abhijit.bal@nhs.net.</nlm:affiliation></affiliation></author><author><name sortKey="David, M Z" sort="David, M Z" uniqKey="David M" first="M Z" last="David">M Z David</name><affiliation><nlm:affiliation>Departments of Medicine, Paediatrics, and Public Health Sciences, University of Chicago, Chicago, IL 60637, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Garau, J" sort="Garau, J" uniqKey="Garau J" first="J" last="Garau">J. Garau</name><affiliation><nlm:affiliation>Department of Medicine, Hospital Universitari Mútua de Terrassa, Plaza Dr Robert 5, Barcelona 08221, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Gottlieb, T" sort="Gottlieb, T" uniqKey="Gottlieb T" first="T" last="Gottlieb">T. Gottlieb</name><affiliation><nlm:affiliation>Department of Microbiology and Infectious Diseases, Concord Hospital, Sydney, NSW 2139, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Mazzei, T" sort="Mazzei, T" uniqKey="Mazzei T" first="T" last="Mazzei">T. Mazzei</name><affiliation><nlm:affiliation>Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Firenze, Firenze, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Scaglione, F" sort="Scaglione, F" uniqKey="Scaglione F" first="F" last="Scaglione">F. Scaglione</name><affiliation><nlm:affiliation>Department of Oncology and Onco-Haematology, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Tattevin, P" sort="Tattevin, P" uniqKey="Tattevin P" first="P" last="Tattevin">P. Tattevin</name><affiliation><nlm:affiliation>Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, 35033 Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gould, I M" sort="Gould, I M" uniqKey="Gould I" first="I M" last="Gould">I M Gould</name><affiliation><nlm:affiliation>Department of Microbiology, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of global antimicrobial resistance</title><idno type="eISSN">2213-7173</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major public health problem. Vancomycin and teicoplanin have been in clinical use for several decades but their drawbacks are well described. In the last 10 years, several antibiotics have been made available for clinical use. Daptomycin and linezolid have been extensively used during this period. Other agents such as ceftaroline, ceftobiprole, dalbavancin, oritavancin, tedizolid and telavancin have been approved by regulatory agencies since 2009. Many others, such as the newer tetracyclines, fluoroquinolones, oxazolidinones and pleuromutilins, are in various stages of development. In addition, an ongoing multicentre trial is investigating the role of combination of vancomycin or daptomycin with β-lactam antibiotics. This review discusses the role of the newer antibiotics, reflecting the views of the 6th MRSA Consensus Conference meeting of the International Society of Chemotherapy MRSA Working Group that took place in 2016.</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">28732783</PMID><DateCreated><Year>2017</Year><Month>07</Month><Day>22</Day></DateCreated><DateRevised><Year>2017</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-7173</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of global antimicrobial resistance</Title><ISOAbbreviation>J Glob Antimicrob Resist</ISOAbbreviation></Journal><ArticleTitle>Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen.</ArticleTitle><Pagination><MedlinePgn>295-303</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S2213-7165(17)30106-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jgar.2017.05.019</ELocationID><Abstract><AbstractText>Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major public health problem. Vancomycin and teicoplanin have been in clinical use for several decades but their drawbacks are well described. In the last 10 years, several antibiotics have been made available for clinical use. Daptomycin and linezolid have been extensively used during this period. Other agents such as ceftaroline, ceftobiprole, dalbavancin, oritavancin, tedizolid and telavancin have been approved by regulatory agencies since 2009. Many others, such as the newer tetracyclines, fluoroquinolones, oxazolidinones and pleuromutilins, are in various stages of development. In addition, an ongoing multicentre trial is investigating the role of combination of vancomycin or daptomycin with β-lactam antibiotics. This review discusses the role of the newer antibiotics, reflecting the views of the 6th MRSA Consensus Conference meeting of the International Society of Chemotherapy MRSA Working Group that took place in 2016.</AbstractText><CopyrightInformation>Copyright © 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bal</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Microbiology, University Hospital Crosshouse, Kilmarnock KA2 0BE, UK. Electronic address: abhijit.bal@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>M Z</ForeName><Initials>MZ</Initials><AffiliationInfo><Affiliation>Departments of Medicine, Paediatrics, and Public Health Sciences, University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garau</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hospital Universitari Mútua de Terrassa, Plaza Dr Robert 5, Barcelona 08221, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottlieb</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Infectious Diseases, Concord Hospital, Sydney, NSW 2139, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzei</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Firenze, Firenze, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scaglione</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Oncology and Onco-Haematology, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tattevin</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, 35033 Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gould</LastName><ForeName>I M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Glob Antimicrob Resist</MedlineTA><NlmUniqueID>101622459</NlmUniqueID><ISSNLinking>2213-7165</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Combination antibiotics</Keyword><Keyword MajorTopicYN="N">MRSA infection</Keyword><Keyword MajorTopicYN="N">New antibiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28732783</ArticleId><ArticleId IdType="pii">S2213-7165(17)30106-6</ArticleId><ArticleId IdType="doi">10.1016/j.jgar.2017.05.019</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000631 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000631 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28732783
|texte= Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28732783" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |